Clinical Trial Update: Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of stereotactic ablative radiotherapy and durvalumab (MEDI4736) for oligometastatic relapse in prostate cancer is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Institut Cancerologie de l'Ouest | Conditions: Node; Prostate, Bone Metastases | Phase 2 | Status: ACTIVE_NOT_RECRUITING